GlaxoSmithKline’s IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday, the Associated Press reported. That leaves just one antibody treatment that is still authorized for use, an Eli Lilly drug that still sees effective, after another Eli Lilly drug and one from Regeneron were deemed ineffective. The BA.2 subvariant accounts for 72% of new U.S. cases, according to the CDC. An FDA panel is to meet Wednesday to discuss the best strategy for dealing with COVID for the rest of the year,the New York Times reported.
The U.S. is averaging 28,693 cases a day, according to a New York Times tracker, down 1% from two weeks ago and higher than Tuesday’s count. Cases are rising in states in the Northeast and South again as BA.2 spreads. The country is averaging 15,383 hospitalizations a day, down 27% from two weeks ago. The daily death toll has fallen below 700 to 602.
On a global basis, total cases rose above 493.7 million and total deaths are above 6.15 million, according to data aggregated by Johns Hopkins University, with the U.S. still leading the way with 80.2 million cases and 982,585 deaths.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0
